For years, the basic arrangement in advanced EGFR-mutated non-small-cell lung cancer has looked fairly tidy. Find the EGFR mutation, prescribe a modern EGFR inhibitor, and let the targeted drug do its elegant work. It is a pleasing architectural plan - precise, efficient, almost minimalist. Then reality barges in through the side door. Tumors adapt. Resistance develops. The renovation goes off schedule.
That is the setup for AENEAS2, a phase 3 trial asking a very practical question: if aumolertinib, a third-generation EGFR tyrosine kinase inhibitor, already works, does adding platinum-pemetrexed chemotherapy help it work longer in untreated advanced EGFR-mutated NSCLC? According to the trial, yes - though not without a bill arriving later in the form of toxicity Li et al., 2026.
The blueprint, before the scaffolding collapsed
EGFR-mutated lung cancers are one of oncology’s clearer success stories. If a tumor carries a sensitizing EGFR mutation - commonly exon 19 deletion or L858R - drugs like osimertinib, furmonertinib, and aumolertinib can shrink disease and delay progression far better than older chemotherapy-first approaches. The catch is that cancer cells are gifted little saboteurs. Give them one route to escape and, sooner or later, many of them will find the fire stairs.
That has pushed researchers toward combination strategies. The logic is not especially mystical. If one treatment blocks the main engine, perhaps a second can interfere with backup systems before the tumor rewires the building.
What AENEAS2 actually found
This open-label, randomized phase 3 study enrolled 624 patients across 60 hospitals in China with untreated, locally advanced or metastatic NSCLC carrying EGFR-sensitive mutations. Patients received either:
- Aumolertinib alone, or
- Aumolertinib plus platinum-pemetrexed chemotherapy
The main result was hard to ignore. Median progression-free survival was:
- 28.9 months with combination therapy
- 18.9 months with aumolertinib alone
That translated to a 53% reduction in the risk of progression or death during the study period, with a hazard ratio of 0.47 and a p value of <0.0001 (Li et al., 2026).
In plain English: adding chemotherapy bought patients roughly 10 extra months before the cancer worsened, at least by this endpoint. In stage IV lung cancer, that is not pocket change.
The part where the ceiling leaks
Now for the less glamorous but more honest portion of the inspection report.
The combination arm caused substantially more side effects, especially blood count suppression. Grade 3-4 decreases in neutrophils, white cells, and platelets were much more common with chemotherapy added. Serious adverse events occurred in 36% of patients on the combination, compared with 17% on monotherapy (Li et al., 2026).
This is not a surprise. Chemotherapy has never pretended to be a gentleman. It arrives with steel-toed boots and tends to step on the bone marrow. The real question is whether the added benefit justifies the extra burden, and that answer will vary from patient to patient. A fit person with high-volume disease may make one calculation. Someone frailer, or deeply protective of day-to-day quality of life, may make another.
Why this matters beyond one drug
AENEAS2 does not appear out of thin air. It joins a growing body of evidence suggesting that EGFR TKI plus chemotherapy can outperform EGFR TKI alone in the first-line setting.
The most practice-shaping comparison remains FLAURA2, where osimertinib plus platinum-pemetrexed improved progression-free survival over osimertinib alone in advanced EGFR-mutant NSCLC (Planchard et al., 2023). Earlier studies with first-generation EGFR inhibitors also pointed in this direction, though with different toxicity profiles and a different therapeutic era in view (Wu et al., 2020).
Reviews over the past few years have framed the broader issue neatly: targeted therapy has become the load-bearing wall in EGFR-mutated lung cancer, but resistance remains the recurring structural crack Passaro et al., 2024. Researchers are trying combinations up front because waiting for the building to fail is, medically speaking, an expensive hobby.
The obvious question: should everyone get the combo?
Not so fast. Progression-free survival is a strong and useful endpoint, but it is not the whole house. We still need overall survival data, longer follow-up, and a sharper sense of which patients benefit most. We also need to understand whether some subgroups - for example, people with brain metastases or specific co-mutations - gain more than others.
And then there is the practical matter of tolerability. A regimen can look magnificent in a Kaplan-Meier curve and still feel rather less magnificent when your neutrophils have fallen through the floorboards.
The bigger picture, with less jargon and more common sense
If these findings hold up over time, AENEAS2 strengthens a simple but consequential idea: in some EGFR-mutated lung cancers, hitting hard early may keep the disease under control longer than precision therapy alone.
That does not mean targeted therapy has failed. Quite the opposite. It means the field is maturing. The first act was about finding the right molecular lock and building a key. The second act is about what to do when the lock starts changing shape, because cancer, with tiresome consistency, refuses to remain politely classified.
For patients, this kind of work matters because treatment choices are no longer just "chemotherapy or not." They are becoming carefully engineered sequences and combinations, each with tradeoffs in time, toxicity, and control. Oncology, as ever, is less a duel than a maintenance project on a very unruly property.
References
-
Li Z, Hu J, Chen J, et al. Aumolertinib with or without chemotherapy in EGFR-mutated advanced non-small-cell lung cancer (AENEAS2): an open-label, multicentre, randomised, controlled, phase 3 trial. Lancet Oncol. 2026. doi: 10.1016/S1470-2045(26)00090-2
-
Planchard D, Feng PH, Karaseva N, et al. Osimertinib with or without chemotherapy in EGFR-mutated advanced NSCLC. N Engl J Med. 2023;389:1935-1948. doi: 10.1056/NEJMoa2321961
-
Wu YL, Cheng Y, Zhou X, et al. Dacomitinib plus chemotherapy or gefitinib plus chemotherapy versus gefitinib alone in advanced non-small-cell lung cancer with EGFR activating mutations. J Clin Oncol. 2020;38(15):1627-1636. doi: 10.1200/JCO.19.01456
-
Passaro A, Mok TSK, Peters S, Popat S, Ahn MJ, de Marinis F. EGFR-mutant non-small-cell lung cancer: treatment evolution and future directions. Nat Rev Clin Oncol. 2024. doi: 10.1038/s41571-024-00852-3
Disclaimer: The image accompanying this article is for illustrative purposes only and does not depict actual experimental results, data, or biological mechanisms.